COVID trial

For information about the trial – Information in Norwegian:

https://oslo-universitetssykehus.no/kliniske-studier/utvikling-av-dna-vaksiner-mot-nye-varianter-av-koronavirus

An open label, Phase 1/2, dose escalation, and dose expansion study to evaluate the safety, reactogenicity and immunogenicity of two SARS-CoV-2 DNA plasmid vaccine candidates, VB10.2129 (C1) and VB10.2210 (C2). Three dose levels will be tested. IM administrations 21 days apart.

ClinicalTrials.gov Identifier: NCT05069623

https://clinicaltrials.gov/ct2/show/NCT05069623